The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. (2022)

First Author: Spencer AJ
Attributed to:  nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19 funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2022.103902

PubMed Identifier: 35228013

Publication URI: http://europepmc.org/abstract/MED/35228013

Type: Journal Article/Review

Volume: 77

Parent Publication: EBioMedicine

ISSN: 2352-3964